Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clin...

Industry: Biotechnology

Sector: Healthcare

Phone: (888) 355-4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

Canverra Oct. 25 at 11:06 AM

$PULM caca de la vaca

1 · Reply

Pilot288 Oct. 24 at 8:01 PM

$PULM 3,100 shares trading hands today. Good luck getting out even if you wanted to. With all the buying the dips and the thanks for the cheap shares, you’ll need 30 days of selling just to get rid of your share of this turd.

2 · Reply

Nakom Oct. 24 at 7:21 PM

$PULM I’m calling it today. Looks like a merger Monday is in the works!!! Good luck fellow longs.

0 · Reply

HomeRunHitterXXXXX Oct. 24 at 5:54 PM

$PULM gap up merger coming?

0 · Reply

hippo_hungry Oct. 24 at 5:26 PM

$PULM gap down coming .. caca 💩 stock

0 · Reply

HomeRunHitterXXXXX Oct. 24 at 4:56 AM

$PULM time for a gap

0 · Reply

ProfessorGamma Oct. 22 at 11:23 PM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $PULM $BAOS $SKK $SLAI Watchlist,

0 · Reply

Nakom Oct. 22 at 9:27 PM

$PULM MNKD and UTHR need us more then we need them. In a very good bargaining position although I truely believe it’s a done deal already. Just a formality of signing on the dotted line. Super bullish.

1 · Reply

Nakom Oct. 22 at 7:08 PM

$PULM Thank you very much for the cheap shares today. May I have some more please.

0 · Reply

Nakom Oct. 22 at 6:31 PM

$PULM Well, the good news is is I was able to pick up 163 shares this morning. The bad news was. I guess there really is not any bad news. All good in Pulmatrix land.

0 · Reply

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 2 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 5 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 6 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 7 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

ENTO

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 1 year ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 1 year ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 2 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 2 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 2 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 3 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 3 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 3 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 3 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 3 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Aug 10, 2021, 9:10 AM EDT - 4 years ago

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

Jul 27, 2021, 10:00 AM EDT - 4 years ago

Pulmatrix appoints Director Anand Varadan

May 11, 2021, 4:35 PM EDT - 4 years ago

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

Canverra Oct. 25 at 11:06 AM

$PULM caca de la vaca

1 · Reply

Pilot288 Oct. 24 at 8:01 PM

2 · Reply

Nakom Oct. 24 at 7:21 PM

$PULM I’m calling it today. Looks like a merger Monday is in the works!!! Good luck fellow longs.

0 · Reply

HomeRunHitterXXXXX Oct. 24 at 5:54 PM

$PULM gap up merger coming?

0 · Reply

hippo_hungry Oct. 24 at 5:26 PM

$PULM gap down coming .. caca 💩 stock

0 · Reply

HomeRunHitterXXXXX Oct. 24 at 4:56 AM

$PULM time for a gap

0 · Reply

ProfessorGamma Oct. 22 at 11:23 PM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $PULM $BAOS $SKK $SLAI Watchlist,

0 · Reply

Nakom Oct. 22 at 9:27 PM

1 · Reply

Nakom Oct. 22 at 7:08 PM

$PULM Thank you very much for the cheap shares today. May I have some more please.

0 · Reply

Nakom Oct. 22 at 6:31 PM

$PULM Well, the good news is is I was able to pick up 163 shares this morning. The bad news was. I guess there really is not any bad news. All good in Pulmatrix land.

0 · Reply

arrosto Oct. 22 at 2:16 PM

$PULM No trades yet?

0 · Reply

Nakom Oct. 22 at 2:01 PM

$PULM You ever think it just might be one person playing games with this stock. Hope he or she gets burned. JMO

0 · Reply

jlonards Oct. 22 at 1:23 PM

$PULM what's the rumor?

1 · Reply

arrosto Oct. 22 at 12:40 PM

$PULM If people are paying above $5 even for a few hundred shares we might be getting close to finally being done with PULM.

1 · Reply

HomeRunHitterXXXXX Oct. 22 at 5:18 AM

$PULM

0 · Reply

HomeRunHitterXXXXX Oct. 21 at 6:06 PM

$PULM fake news he works for CNN 😂

0 · Reply

Nakom Oct. 21 at 11:29 AM

$PULM Now I know we are getting close when fake news starts getting reported. Could November be the month to remember for Pulmatrix. Stay tuned.

0 · Reply

madan_shatri Oct. 21 at 4:44 AM

$PULM So has the reverse merger deal fallen apart ? End of road ? Whats this ?

3 · Reply

Nakom Oct. 20 at 8:56 PM

$PULM So no merger Monday today. I’m not giving up. It’s going to happen. Keep the faith everyone!!!

0 · Reply

arrosto Oct. 20 at 7:16 PM

$PULM Getting close

0 · Reply

Nakom Oct. 20 at 7:04 PM

$PULM Super bullish!!! It’s going to happen very soon.

0 · Reply

HomeRunHitterXXXXX Oct. 20 at 3:05 AM

$PULM let’s do this

0 · Reply

Market Cap	17.67M
Revenue (ttm)	7.81M
Net Income (ttm)	-6.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-88.86%
Debt to Equity Ratio	0.00

Volume	3,200
Avg Vol	14,422
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	46%
Beta	1.64
Analysts	Strong Buy
Price Target	$10.00